Donald Danforth Center receives $11.9M funding for Virus Resistant Cassava for Africa project

Project aims to develop virus resistant cassava to help farmers provide food for their families

The Donald Danforth Plant Science Center announced today that it has received additional funding totaling $11.9 million for the Virus Resistant Cassava for Africa (VIRCA) project to advance its work to improve the health and wellbeing of farmers, their families, and other consumers of cassava living in Sub Saharan Africa.

Funds will be used to support Phase II of the humanitarian effort to develop and deliver farmer-preferred cassava varieties enhanced to resist serious plant virus diseases that are greatly reducing crop yield and increasing the threat of poverty and famine.

The additional funding came from the Bill & Melinda Gates Foundation ($5.6 million), The Monsanto Fund ($5.4 million) and the Howard Buffett Foundation ($860,000). VIRCA is also supported by USAID from the American people ($2.5 million).

Two products will be developed in VIRCA-II. The first product will incorporate siRNA-based resistance to CBSD in the popular cultivar TME204, which has natural resistance to CMD and is favored by farmers in Uganda and the Lake Victoria region. "Delivery of CBSD resistant TME204 is the fastest route to address the CBSD epidemic" said Dr. Anton Bua, the Ugandan Cassava Research Team Leader in charge of field trials and communication for the project in East Africa. A second product will be developed in the highly popular, traditional Ebwanateraka cultivar in which virus sequences will be stacked to impart resistance to both CBSD and CMD. Known as the "Queen" of cassava for its taste and texture as well as its flexibility in harvesting time, Ebwanateraka has been virtually wiped out in the Uganda region due to the two viral diseases.

VIRCA-II is a collaboration between researchers at the Donald Danforth Plant Science Center in St Louis, MO, the NaCRRI, and the Kenya Agricultural Research Institute (KARI). The team will build on achievements made in VIRCA-I, during which gene silencing demonstrated success in controlling both diseases in transgenic cassava plants. Control of CMD associated with several-fold improvement in storage root yields was recently demonstrated in early field trials in Uganda.

"We are grateful for the support of our many partners for this important project. I have witnessed the devastation caused by CMD and CBSD, wiping out entire harvests, leaving many people on the verge of starvation. Our team is confident that the cassava we develop will improve the lives of millions of people allowing them to not only grow adequate food, but also to increase productivity so they might have enough money left over to educate their children and afford good medical care for malaria and other diseases they face," said Dr. Claude Fauquet, principal investigator and director of ILTAB at The Donald Danforth Plant Science Center, who serves as the lead investigator.

Cassava is one of the most important staple food crops for more than 200 million sub-Saharan Africans who derive 25 percent of their daily calorie intake from the starchy tuberous roots. In the East African countries of Uganda, Kenya, Tanzania, Mozambique, Rwanda, Burundi and Malawi, approximately 130 million people depend on the crop and produce nearly 30 metric tons of cassava annually. Cassava also contributes more than any other single crop to household income, with 63 percent of households selling cassava products.

Despite its natural drought tolerance and ability to grow well on marginal lands, cassava is susceptible to various pathogens. At least one third of the continental harvest is lost each year to Cassava Mosaic Disease (CMD) alone. Cassava Brown Streak Disease (CBSD), another viral cassava disease, is considered to be among the most dangerous plant diseases in the world for the threat it poses to food and economic security throughout Africa. In the Lake Victoria area in East Africa, more than seven million people are at risk of famine each year because of CBSD threats. The enormous urgency posed by these viruses demands that appropriate tools be applied to solve the problem.

"In Uganda, we eat cassava two or three times per day. Restoring and improving cassava productivity will be key for the improving the economic progress of the country and the region," said Dr. Titus Alicai, project lead, National Crop Resources Research Institute (NaCRRI).

In East Africa CBSD is considered a more immediate threat to cassava production than CMD because of the significant increase in geographical distribution in recent years and the dramatic effect this virus has on both yield and quality of cassava storage roots. CBSD symptoms are more subtle than CMD and may be hard to detect on leaves and stems, while causing severe necrosis in the edible storage roots and to the stems that are used to produce the next crop. Root necrosis, which can remain unnoticed until harvest, has a substantial impact on families that are dependent on the crop. Furthermore, stem cuttings produced from infected plants grow poorly or not at all, increasing chances that farmers will abandon the cultivation of cassava in severely affected regions, such as around Lake Victoria.

The enhanced cassava cultivars created by the VIRCA project will be readily available to farmers in the same way traditional cassava is being offered today and will have no royalty fees. This means farmers will be able to freely multiply, save and share their planting materials.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metagenomic sequencing improves detection of rare pathogens in CNS infections